URA7 Antibody

What is URA7 and why would researchers need antibodies against it?

URA7 encodes one of two CTP synthases in Saccharomyces cerevisiae (the other being URA8). CTP synthases catalyze the rate-limiting step in pyrimidine nucleotide biosynthesis, converting UTP to CTP . URA7 has gained particular interest because it forms distinct cytoplasmic filaments under specific cellular conditions, particularly during nutrient limitation . Antibodies against URA7 enable researchers to:

• Detect and quantify URA7 protein expression in different growth conditions

• Study URA7 localization and filament formation dynamics

• Examine interactions between URA7 and other cellular components

• Investigate the role of URA7 in nucleotide metabolism and DNA replication fidelity

How can researchers validate the specificity of URA7 antibodies?

When validating URA7 antibodies, consider these methodological approaches:

• Genetic controls: Test antibody reactivity in wild-type vs. ura7Δ yeast strains. A specific antibody will show signal in wild-type cells but not in ura7Δ deletion mutants .

• Recombinant protein controls: Express and purify recombinant URA7 (with and without tags) to test antibody recognition in Western blots and immunoprecipitation.

• Cross-reactivity assessment: Test reactivity against URA8, the paralog of URA7, to ensure antibody specificity, as both encode CTP synthases with potential structural similarities .

• Epitope mapping: Confirm which region of URA7 the antibody recognizes to predict potential cross-reactivity and ensure recognition of both filamentous and non-filamentous forms.

What sample preparation techniques optimize URA7 detection in yeast cells?

For optimal detection of URA7 in yeast cells:

• Growth conditions: Consider that URA7 filament formation is heavily influenced by culture conditions. Log-phase cultures show minimal URA7 filaments (0.00% of cells), while saturated cultures show significant filament formation (15.20% of cells) .

• Fixation methods: For immunofluorescence, use gentle fixation methods (e.g., low concentration paraformaldehyde) to preserve filamentous structures which may be disrupted by harsh fixation.

• Cell wall removal: Optimize spheroplasting protocols using zymolyase or lyticase to allow antibody penetration while preserving cellular structures.

• Extraction buffers: For Western blotting, use buffers containing protease inhibitors and, potentially, phosphatase inhibitors if studying URA7 regulation.

• Subcellular fractionation: Consider that URA7 can exist in both soluble and filamentous forms, requiring different extraction techniques for complete recovery .

How can URA7 antibodies be used to study filament formation dynamics?

URA7 forms distinct cytoplasmic filaments that are separate from other filament-forming proteins like Psa1p and Glt1p . To study these dynamics:

• Time-course immunofluorescence: Combine URA7 antibodies with time-lapse microscopy to capture filament formation in response to stimuli like glucose depletion, which is a potent inducer of URA7 filament formation .

• Co-localization studies: Use URA7 antibodies in combination with markers for other cellular structures to determine spatial relationships. Research indicates URA7 forms filaments distinct from those formed by Psa1p, Glt1p, and eIF2/2B complexes .

• Quantitative analysis: Implement the following approach for quantifying filament formation:

• Electron microscopy: Use immunogold labeling with URA7 antibodies to study filament ultrastructure beyond the resolution of light microscopy.

• Live cell imaging: Complement antibody studies by comparing with URA7-GFP dynamics, noting that GFP tagging does not affect URA7 function as demonstrated by viability of URA7::GFP; ura8Δ yeast strains .

What methodological approaches can resolve the correlation between URA7 filament formation and CTP synthase activity?

This question addresses a fundamental structure-function relationship:

• Activity assays with immunoprecipitated protein: Use URA7 antibodies to isolate the protein from cells under filament-forming and non-filament conditions, then measure CTP synthase activity in vitro.

• In situ activity correlation: Combine immunofluorescence for URA7 with metabolic labeling to correlate filament presence with CTP synthesis rates in individual cells.

• Nucleotide pool analysis: Compare CTP/UTP ratios in cells with different levels of URA7 filament formation. Research shows ura7Δ mutants exhibit a 66% reduction in CTP levels, demonstrating URA7's significant role in pyrimidine metabolism .

• Structure-guided antibody selection: Select antibodies recognizing different URA7 epitopes to determine if filament formation involves conformational changes affecting enzymatic active sites.

• Stress response correlation: Evaluate whether filament formation (detected by antibodies) correlates with activation of stress response pathways, metabolic shifts, or changes in growth rate.

How can researchers address potential epitope masking in filamentous versus soluble URA7?

When URA7 forms filaments, certain epitopes may become inaccessible:

• Epitope mapping under different conditions: Test antibody binding to URA7 under conditions promoting filamentous (saturation or glucose depletion) versus soluble forms (log phase growth) .

• Multiple antibody approach: Use antibodies targeting different URA7 regions to ensure detection regardless of conformational state.

• Native versus denaturing conditions: Compare antibody performance in applications maintaining native structure (immunofluorescence, native PAGE) versus denaturing conditions (Western blot, SDS-PAGE).

• Accessibility enhancement techniques: If epitope masking occurs in filaments, explore gentle permeabilization techniques to improve antibody access without disrupting filament structure.

• Correlative microscopy: Combine electron and light microscopy with different antibodies to create comprehensive models of URA7 organization in filaments.

How can URA7 antibodies contribute to understanding the role of URA7 in maintaining genome stability?

URA7 deletion causes severe mutator phenotypes and DNA damage response activation :

• Chromatin association studies: Use URA7 antibodies in chromatin immunoprecipitation (ChIP) to determine if URA7 associates with replication forks or DNA damage sites.

• Cell cycle analysis: Combine URA7 antibodies with cell cycle markers to examine if URA7 localization or filament formation correlates with specific cell cycle phases. Previous research indicates ura7Δ mutants have extended S-phase, suggesting replication problems .

• Co-immunoprecipitation: Use URA7 antibodies to identify protein interactions with DNA replication or repair machinery components.

• DNA damage response correlation: Compare URA7 localization before and after DNA damage induction. Research shows URA7 deletion activates the DNA damage response pathway .

• Mutation spectrum analysis: While antibodies cannot directly reveal mutation patterns, they can help correlate URA7 expression/localization with mutation frequency in reporter systems. Data shows ura7Δ strains exhibit dramatically increased G:C-to-A:T transitions, comprising ~95% of mutations .

What methodological challenges exist when using URA7 antibodies to study nucleotide pool imbalance effects?

URA7 deletion results in significant nucleotide pool imbalances, particularly decreased CTP levels :

• Temporal correlation: Design experiments that correlate URA7 detection (by antibodies) with simultaneous nucleotide pool measurements to establish temporal relationships.

• Subcellular compartmentalization: Develop fractionation protocols combined with immunolocalization to determine if nucleotide pool imbalances vary in cellular compartments where URA7 is present versus absent.

• Metabolic flux analysis: Combine URA7 antibody studies with isotope-labeled precursor incorporation to measure nucleotide synthesis rates in different cellular compartments.

• Genetic background considerations: When using URA7 antibodies in mutant backgrounds (e.g., msh6Δ, pol3-L612M), account for potential changes in URA7 expression or localization that might influence interpretation.

• Data normalization challenges: When quantifying URA7 in cells with nucleotide imbalances, carefully select reference genes/proteins that aren't affected by these metabolic changes for accurate normalization.

What are the critical considerations for immunoprecipitation of URA7 from yeast lysates?

Successful URA7 immunoprecipitation requires:

• Buffer optimization: Test different lysis buffers to efficiently solubilize URA7 while preserving antibody recognition. Consider that URA7 forms filaments under certain conditions, which may require specialized extraction approaches .

• Cross-linking considerations: For studying URA7 interaction partners, optimize formaldehyde or other cross-linking methods to capture transient interactions while maintaining antibody epitope recognition.

• Nutrient status standardization: Given that URA7 filament formation is strongly induced by glucose depletion , standardize growth conditions prior to harvest to ensure reproducible results.

• Antibody orientation and coupling: Test different coupling strategies (direct coupling, protein A/G beads) to optimize URA7 capture while minimizing non-specific binding.

• Validation approaches: Use URA7-GFP strains as positive controls for immunoprecipitation protocol optimization, as URA7-GFP maintains functionality based on viability of URA7::GFP; ura8Δ yeast strains .

How should researchers approach URA7 antibody selection for studying potential post-translational modifications?

When investigating potential URA7 post-translational modifications:

• Modification-specific vs. general antibodies: Determine whether to use antibodies recognizing all URA7 forms or only specific modified versions (phosphorylated, ubiquitinated, etc.).

• Epitope location consideration: Select antibodies whose epitopes are unlikely to be masked by potential modifications of interest.

• Validation in modification-rich conditions: Test antibody recognition under conditions where modifications may be enriched (different growth phases, stress conditions).

• Combination with modification-specific stains: Use URA7 antibodies in combination with modification-specific stains or antibodies (anti-phospho, anti-ubiquitin) to correlate URA7 localization with modification status.

• Sample preparation adaptations: Modify extraction protocols to preserve labile modifications by including appropriate inhibitors (phosphatase inhibitors, deubiquitinase inhibitors).

How can researchers effectively use URA7 antibodies for comparative studies between URA7 and URA8?

URA7 and URA8 both encode CTP synthases in yeast but show distinct regulation and filament formation patterns :

• Specificity verification: Thoroughly validate antibody specificity to ensure URA7 antibodies don't cross-react with URA8 despite their similar functions.

• Co-localization approaches: Use differentially labeled antibodies against URA7 and URA8 to determine if and when these paralogs co-localize under different conditions.

• Quantitative comparison: Implement quantitative immunoblotting to compare expression levels of URA7 versus URA8 in different growth conditions and genetic backgrounds.

• Comparative filament analysis: Design experiments comparing filament formation between URA7 and URA8. Data shows both form filaments in saturation (15.20% and 16.40% of cells, respectively) but not during log phase .

• Strain-specific considerations: When working with deletion strains, consider that:

  • ura7Δ strains are viable but show reduced CTP levels and increased mutation rates

  • ura8Δ strains are viable

  • ura7Δ ura8Δ double mutants are inviable, indicating functional redundancy

What methodological approaches can resolve potential artifacts when using URA7 antibodies versus GFP-tagged URA7?

Both approaches have complementary strengths and limitations:

• Functional validation: Confirm that URA7-GFP remains functional (URA7::GFP; ura8Δ strains are viable ), but verify whether antibody binding affects URA7 function in vitro.

• Structural comparisons: Use both detection methods to determine if GFP tagging alters URA7 filament morphology compared to untagged URA7 detected by antibodies.

• Dynamic range assessment: Compare detection sensitivity between antibody-based methods and GFP fluorescence across different expression levels and conditions.

• Fixation effects: Systematically compare live-cell imaging of URA7-GFP with fixed-cell antibody staining to identify potential fixation artifacts in filament structures.

• Combined approaches: When possible, use both methods in the same experiment (e.g., URA7-GFP expressing cells stained with URA7 antibodies) to directly compare detection efficiency and identify potential discrepancies.